The National Institute for Health and Care Excellence

MHRA and NICE aligned pathway: how it's working in practice

Although the aligned pathway is central to our work, the benefits of improved collaboration between MHRA and NICE go beyond it. A recent example is aficamten, a new daily pill for people with ...
National Institute for Health and Care Excellence

Published guidance, NICE advice and quality standards

Digital technologies to support home monitoring of vision changes for people with advanced dry age-related macular degeneration: early-use assessment HTG781 17 September 2026 17 September 2026 ...
National Institute for Health and Care Excellence

Weekly insulin jab could cut injections from 365 a year to just 52

Hundreds of thousands of people with type 2 diabetes could swap daily insulin injections for a once-a-week jab, following a NICE recommendation today (Thursday, 20 August). The switch could cut the ...
National Institute for Health and Care Excellence

Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy (rapid review of TA992) [GID-TA12551]

Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy (rapid review of TA992) [GID-TA12551] ...
National Institute for Health and Care Excellence

News, blogs and podcasts

Around 1,000 people with HER2-low advanced breast cancer can now be offered Enhertu after NICE recommended it for routine NHS use. People with obsessive-compulsive disorder (OCD) and body dysmorphic ...
National Institute for Health and Care Excellence

Ibrutinib with R-CHOP for untreated mantle cell lymphoma when a stem cell transplant is suitable

There is a simple discount patient access scheme for ibrutinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
The National Institute for Health and Care Excellence

How to reveal your market access blind spots

Learn how NICE Advice’s system engagement service helps life sciences companies spot NHS adoption barriers before they become roadblocks.
The National Institute for Health and Care Excellence

NICE recommends Enhertu for people with HER2-low advanced breast cancer

Around 1,000 people with HER2-low advanced breast cancer can now be offered Enhertu after NICE recommended it for routine NHS use.
National Institute for Health and Care Excellence

Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults

This guideline covers general principles for prescribing and managing withdrawal from opioids, benzodiazepines, gabapentinoids, Z‑drugs and antidepressants in primary and secondary care. It does not ...
National Institute for Health and Care Excellence

COVID-19 rapid guideline: reducing the risk of venous thromboembolism in over 16s with COVID-19

This guideline has been updated and replaced by NICE rapid guideline on managing COVID-19 (NG191) ...
National Institute for Health and Care Excellence

Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over

Evidence-based recommendations on brexucabtagene autoleucel (Tecartus) for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over. There is a managed access ...
National Institute for Health and Care Excellence

Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic treatment

There is a simple discount patient access scheme for lisocabtagene maraleucel. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...